In 2023, we continued to commit to building families and helping people live better lives by launching two first-in-class medicines, marking the start of an exciting phase of growth.
Read our 2023 #AnnualReport: bit.ly/4cRIRCb
“We aren’t just solving an issue for women, we are solving an issue for the population of the world.”
Per Falk (@ferring) discusses the need for a multilateral approach to global health policy. #wef24
#NEWS: We’re pleased to announce our collaboration with @pharmabiome. This R&D agreement builds on PharmaBiome’s technology to develop microbiome-based therapeutics, helping patients with gastroenterological diseases live better lives.
bit.ly/3NndDYN
The #MicrobiomeConnectUSA conference takes place this week in Boston, MA. Our VP of Microbiome Research @KenBlountPhD and @Rebiotix Senior Director of Microbiome Data Science, @T_L_Ward will discuss recent innovations in the #microbiome field.
This post is intended for HCPs only